Summary: An antilipemic agent that lowers CHOLESTEROL and TRIGLYCERIDES. It decreases LOW DENSITY LIPOPROTEINS and increases HIGH DENSITY LIPOPROTEINS.

Top Publications

  1. Haim M, Boyko V, Goldbourt U, Battler A, Behar S. Predictive value of elevated white blood cell count in patients with preexisting coronary heart disease: the Bezafibrate Infarction Prevention Study. Arch Intern Med. 2004;164:433-9 pubmed
    ..The aim of the present study was to investigate the association between WBC count and subsequent coronary events and total mortality in a large cohort of patients with CHD...
  2. Noguchi T, Kobayashi J, Yagi K, Nohara A, Yamaaki N, Sugihara M, et al. Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover . Atherosclerosis. 2011;217:165-70 pubmed publisher
    b>Bezafibrate and fenofibrate show different binding properties against peroxisome proliferator-activated receptor subtypes, which could cause different clinical effects on circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) ..
  3. Ayaori M, Momiyama Y, Fayad Z, Yonemura A, Ohmori R, Kihara T, et al. Effect of bezafibrate therapy on atherosclerotic aortic plaques detected by MRI in dyslipidemic patients with hypertriglyceridemia. Atherosclerosis. 2008;196:425-33 pubmed
    ..Using MRI, we investigated the effects of bezafibrate on aortic plaques in 22 dyslipidemic patients...
  4. Cabrero A, Cubero M, Llaverias G, Jové M, Planavila A, Alegret M, et al. Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages. Metabolism. 2003;52:652-7 pubmed
    ..We compared the effects of three PPAR activators (bezafibrate, fenofibrate, and troglitazone) on the mRNA levels of genes involved in lipid metabolism in primary human ..
  5. Hays T, Rusyn I, Burns A, Kennett M, Ward J, Gonzalez F, et al. Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis. Carcinogenesis. 2005;26:219-27 pubmed
    ..Interestingly, administration of the less specific PPARalpha agonist, bezafibrate, leads to a modest induction of PPARalpha target genes in the absence of PPARalpha expression...
  6. Koren Morag N, Tanne D, Graff E, Goldbourt U. Low- and high-density lipoprotein cholesterol and ischemic cerebrovascular disease: the bezafibrate infarction prevention registry. Arch Intern Med. 2002;162:993-9 pubmed
  7. Kurihara T, Maeda A, Shigemoto M, Yamashita K, Hashimoto E. Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy. Am J Gastroenterol. 2002;97:212-4 pubmed
  8. Meco J, Vila R, Pujol R, Bros R, Domenech P, Fiol C, et al. Improvement in endothelial dysfunction in patients with hypoalphalipoproteinemia and coronary artery disease treated with bezafibrate. J Cardiovasc Pharmacol. 2001;38:250-8 pubmed
    ..dilatation (FMD) in response to reactive hyperemia was measured by brachial ultrasound, before and after bezafibrate treatment (400 mg daily for 6 months) in 16 patients with CAD and impaired FMD (<10%)...
  9. Jonkers I, de Man F, van der Laarse A, Frolich M, Gevers Leuven J, Kamper A, et al. Bezafibrate reduces heart rate and blood pressure in patients with hypertriglyceridemia. J Hypertens. 2001;19:749-55 pubmed
    ..The present study was undertaken to investigate the effects of bezafibrate on hemodynamics in relation to insulin, FFA, sympathetic activity, renal sodium absorption, cyclic-GMP (cGMP) ..

More Information


  1. Gobin Limballe S, Djouadi F, Aubey F, Olpin S, Andresen B, Yamaguchi S, et al. Genetic basis for correction of very-long-chain acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a genotype-based therapy. Am J Hum Genet. 2007;81:1133-43 pubmed
    ..Recent data suggest that bezafibrate could improve the FAO capacities in beta-oxidation-deficient cells, by enhancing the residual level of mutant ..
  2. Haim M, Benderly M, Tanne D, Matas Z, Boyko V, Fisman E, et al. C-reactive protein, bezafibrate, and recurrent coronary events in patients with chronic coronary heart disease. Am Heart J. 2007;154:1095-101 pubmed
    ..and subsequent coronary risk in patients with chronic coronary heart disease (CHD), (2) the effect of long-term bezafibrate treatment on CRP levels, and (3) to evaluate the consequences of change in CRP level over time on subsequent ..
  3. Lambropoulou D, Hernando M, Konstantinou I, Thurman E, Ferrer I, Albanis T, et al. Identification of photocatalytic degradation products of bezafibrate in TiO(2) aqueous suspensions by liquid and gas chromatography. J Chromatogr A. 2008;1183:38-48 pubmed publisher
    In the present study the photocatalytic degradation of bezafibrate (BZF), a lipid regulator agent, has been investigated using TiO(2) suspensions and simulated solar light...
  4. Tenenbaum A, Boyko V, Fisman E, Goldenberg I, Adler Y, Feinberg M, et al. Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?. Cardiovasc Diabetol. 2008;7:18 pubmed publisher
    ..In animal studies the lipid-lowering PPAR ligand bezafibrate suppressed colonic tumors. However, the effect of bezafibrate on colon cancer development in humans is unknown...
  5. Goldenberg I, Benderly M, Sidi R, Boyko V, Tenenbaum A, Tanne D, et al. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial). Am J Cardiol. 2009;103:41-5 pubmed publisher
    ..9-year follow-up period in 3,020 patients with CAD enrolled in the Bezafibrate Infarction Prevention (BIP) trial was related to changes in lipid levels during the study...
  6. Kawashiri M, Kobayashi J, Nohara A, Noguchi T, Tada H, Nakanishi C, et al. Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: result from a crossover study. Clin Chim Acta. 2011;412:1068-75 pubmed publisher
    We elucidated the difference between the effects of bezafibrate and atorvastatin in hypertriglyceridemia with apoE2/2 and 3/3.
  7. Hara S, Takahashi T, Amita M, Igarashi H, Tsutsumi S, Kurachi H. Bezafibrate restores the inhibition of FSH-induced follicular development and steroidogenesis by tumor necrosis factor-alpha through peroxisome proliferator-activated receptor-gamma pathway in an in vitro mouse preantral follicle culture. Biol Reprod. 2011;85:895-906 pubmed publisher
    We recently reported that bezafibrate, a lipid-lowering drug of the fibrate class, administered in addition to clomiphene citrate (CC) successfully induced ovulation in CC-resistant polycystic ovary syndrome (PCOS) patients...
  8. Bastin J, Aubey F, Rotig A, Munnich A, Djouadi F. Activation of peroxisome proliferator-activated receptor pathway stimulates the mitochondrial respiratory chain and can correct deficiencies in patients' cells lacking its components. J Clin Endocrinol Metab. 2008;93:1433-41 pubmed publisher
    ..The mitochondrial respiratory chain (RC) disorders are the largest group of inborn errors of metabolism and still remain without treatment in most cases...
  9. Kehely A, MacMahon M, Barbir M, Wray R, Hunt B, Prescott R, et al. Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemia. QJM. 1995;88:421-7 pubmed
    The safety and efficacy of combined bezafibrate-simvastatin therapy was evaluated in 49 patients with diet-resistant mixed hyperlipidaemia (type IIb)...
  10. Tenenbaum A, Fisman E, Boyko V, Benderly M, Tanne D, Haim M, et al. Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med. 2006;166:737-41 pubmed are available regarding the short-term efficacy of the peroxisome proliferator-activated receptor ligand bezafibrate on IR, and its long-term effect is unknown...
  11. Murakami H, Murakami R, Kambe F, Cao X, Takahashi R, Asai T, et al. Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC. Biochem Biophys Res Commun. 2006;341:973-8 pubmed
    ..Neither bezafibrate nor WY-14643 activated AMPK in HUVEC...
  12. Djouadi F, Aubey F, Schlemmer D, Ruiter J, Wanders R, Strauss A, et al. Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders. Hum Mol Genet. 2005;14:2695-703 pubmed
    ..We demonstrate that addition of bezafibrate or fenofibric acid in the culture medium induced a dose-dependent (up to 3-fold) increase in palmitate ..
  13. Mori Y, Oana F, Matsuzawa A, Akahane S, Tajima N. Short-term effect of bezafibrate on the expression of adiponectin mRNA in the adipose tissues: a study in spontaneously type 2 diabetic rats with visceral obesity. Endocrine. 2004;25:247-51 pubmed
    The effect of short-term bezafibrate (BF) administration over time on the expression of adiponectin mRNA in the tissues was examined in Otsuka Long Evans Tokushima Fatty (OLETF) rats...
  14. Scatena R, Bottoni P, Martorana G, Ferrari F, De Sole P, Rossi C, et al. Mitochondrial respiratory chain dysfunction, a non-receptor-mediated effect of synthetic PPAR-ligands: biochemical and pharmacological implications. Biochem Biophys Res Commun. 2004;319:967-73 pubmed
    ..These data could afford an explanation of biochemical and toxicological aspects related to the therapeutic use of synthetic PPAR-ligands and suggest a revision of PPAR pathophysiologic mechanisms...
  15. Tenenbaum A, Motro M, Fisman E, Schwammenthal E, Adler Y, Goldenberg I, et al. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 2004;109:2197-202 pubmed
    ..The goal of this study was to evaluate the effect of the peroxisome proliferator-activated receptor ligand bezafibrate on the progression of impaired fasting glucose phase to type 2 diabetes in patients with coronary artery ..
  16. Cortellaro M, Cofrancesco E, Boschetti C, Cortellaro F, Mancini M, Mariani M, et al. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination. Thromb Haemost. 2000;83:549-53 pubmed
    We studied the effects of fluvastatin and bezafibrate in monotherapy and in combination on plasma fibrinogen, t-plasminogen activator inhibitor (PAI-1) and C reactive protein (CRP) in patients with coronary artery disease (CAD) and mixed ..
  17. Tanne D, Benderly M, Goldbourt U, Boyko V, Brunner D, Graff E, et al. A prospective study of plasma fibrinogen levels and the risk of stroke among participants in the bezafibrate infarction prevention study. Am J Med. 2001;111:457-63 pubmed
    ..We sought to determine if plasma fibrinogen is a marker of increased risk or a direct causative risk factor for stroke...
  18. Mohrschladt M, Weverling Rijnsburger A, de Man F, Stoeken D, Sturk A, Smelt A, et al. Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy. Atherosclerosis. 2000;148:413-9 pubmed
    ..In contrast, the study suggests that very-low-density lipoprotein (VLDL) in hypertriglyceridemic patients augments TNF-alpha production...
  19. Johri A, Calingasan N, Hennessey T, Sharma A, Yang L, Wille E, et al. Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease. Hum Mol Genet. 2012;21:1124-37 pubmed publisher
    ..We tested whether pharmacologic treatment with the pan-PPAR agonist bezafibrate would correct a deficiency of PGC-1? and exert beneficial effects in a transgenic mouse model of HD...
  20. Chikahisa S, Tominaga K, Kawai T, Kitaoka K, Oishi K, Ishida N, et al. Bezafibrate, a peroxisome proliferator-activated receptors agonist, decreases body temperature and enhances electroencephalogram delta-oscillation during sleep in mice. Endocrinology. 2008;149:5262-71 pubmed publisher
    ..PPARs play a critical role in lipid and glucose metabolism. We examined whether chronic treatment with bezafibrate, a PPAR agonist, would alter sleep and body temperature (BT)...
  21. Scatena R, Nocca G, Sole P, Rumi C, Puggioni P, Remiddi F, et al. Bezafibrate as differentiating factor of human myeloid leukemia cells. Cell Death Differ. 1999;6:781-7 pubmed
    b>Bezafibrate belongs to the class of fibric acid derivatives usually used as antihyperlipidemia agents...
  22. Nystrom T, Bratt G, Sjoholm A. Bezafibrate-induced improvement in glucose uptake and endothelial function in protease inhibitor-associated insulin resistance. J Intern Med. 2002;252:570-4 pubmed serum triglycerides was seen along with a significant improvement in glucose uptake following treatment with bezafibrate for 3 months. This improvement may be a consequence of the Randle effect, i.e...
  23. Khanim F, Hayden R, Birtwistle J, Lodi A, Tiziani S, Davies N, et al. Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia. PLoS ONE. 2009;4:e8147 pubmed publisher
    ..In particular, therapies that have anti-leukaemic activity but that, unlike conventional chemotherapy, do not impair normal haemopoiesis...
  24. Goldenberg I, Boyko V, Tennenbaum A, Tanne D, Behar S, Guetta V. Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial. Arch Intern Med. 2009;169:508-14 pubmed publisher
    ..We hypothesized that the degree of HDL-C response to bezafibrate is independently associated with subsequent long-term mortality.
  25. Tenenbaum A, Motro M, Fisman E, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med. 2005;165:1154-60 pubmed
    ..We evaluated the effect of bezafibrate retard, a fibric acid derivative, on the incidence of MI in patients with MS enrolled in the Bezafibrate ..
  26. Miida T, Sakai K, Ozaki K, Nakamura Y, Yamaguchi T, Tsuda T, et al. Bezafibrate increases prebeta 1-HDL at the expense of HDL2b in hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 2000;20:2428-33 pubmed
    ..Because bezafibrate elevates lipase activity, it may increase prebeta1-HDL at the expense of HDL(2)...
  27. Haim M, Tanne D, Boyko V, Reshef T, Goldbourt U, Leor J, et al. Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease. Data from the Bezafibrate Infarction Prevention (BIP) Study. J Am Coll Cardiol. 2002;39:1133-8 pubmed
    ..The goal of this study was to assess soluble intercellular adhesion molecule-1 (sICAM-1) level as a predictor of future acute coronary events in patients with chronic coronary heart disease (CHD)...
  28. Jamshidi Y, Flavell D, Hawe E, MacCallum P, Meade T, Humphries S. Genetic determinants of the response to bezafibrate treatment in the lower extremity arterial disease event reduction (LEADER) trial. Atherosclerosis. 2002;163:183-92 pubmed
    Genetic determinants of baseline levels and the fall in plasma triglyceride and fibrinogen levels in response to bezafibrate treatment were examined in 853 men taking part in the lower extremity arterial disease event reduction (LEADER) ..
  29. Kanda T, Yokosuka O, Imazeki F, Saisho H. Bezafibrate treatment: a new medical approach for PBC patients?. J Gastroenterol. 2003;38:573-8 pubmed
    A new medical approach to primary biliary cirrhosis (PBC) has been desired. We investigated the feasibility of using combination ursodeoxycholic acid (UDCA)-bezafibrate therapy in patients with PBC nonresponsive to UDCA monotherapy.
  30. Mulligan H, Tisdale M. Effect of the lipid-lowering agent bezafibrate on tumour growth rate in vivo. Br J Cancer. 1991;64:1035-8 pubmed
    The growth rate of the MAC16 tumour in cachectic animals was significantly enhanced by the hypolipidemic agent bezafibrate, while the growth rate of a histologically similar tumour, the MAC13, which grows without an effect on host body ..
  31. Teramoto T, Shirai K, Daida H, Yamada N. Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study. Cardiovasc Diabetol. 2012;11:29 pubmed publisher
    The hypoglycemic effect of bezafibrate is well established, but administration to a large population of patients with diabetes has not been reported...
  32. Still K, Grabowski P, Mackie I, Perry M, Bishop N. The peroxisome proliferator activator receptor alpha/delta agonists linoleic acid and bezafibrate upregulate osteoblast differentiation and induce periosteal bone formation in vivo. Calcif Tissue Int. 2008;83:285-92 pubmed publisher
    ..The PPARalpha/delta agonists linoleic acid (LA) and bezafibrate (Bez) were then administered to intact male rats by daily s.c...
  33. Zabielski P, Baranowski M, Zendzian Piotrowska M, Błachnio Zabielska A, Gorski J. Bezafibrate decreases growth stimulatory action of the sphingomyelin signaling pathway in regenerating rat liver. Prostaglandins Other Lipid Mediat. 2008;85:17-25 pubmed
    ..The aim of the present study was to investigate the effect of PPARalpha activation by bezafibrate on the sphingomyelin signaling pathway during the first 24h of liver regeneration after PH in the rat...
  34. Roglans N, Vázquez Carrera M, Alegret M, Novell F, Zambon D, Ros E, et al. Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients. Eur J Clin Pharmacol. 2004;59:855-61 pubmed
  35. Djouadi F, Bonnefont J, Thuillier L, Droin V, Khadom N, Munnich A, et al. Correction of fatty acid oxidation in carnitine palmitoyl transferase 2-deficient cultured skin fibroblasts by bezafibrate. Pediatr Res. 2003;54:446-51 pubmed
    ..In the present study, we hypothesized that the hypolipidemic drug bezafibrate, acting as an activator of the peroxisome proliferator-activated receptor alpha might stimulate FAO in CPTII-..
  36. Tenenbaum A, Fisman E, Motro M. Bezafibrate and simvastatin: different beneficial effects for different therapeutic aims. J Clin Endocrinol Metab. 2004;89:1978; author reply 1978-9 pubmed
  37. Charach G, Grosskopf I, Rotmensch H, Kitzis I, Weintraub M. Bezafibrates cause moderate, reversible impairment in renal function in patients without prior renal disease. Nephron Clin Pract. 2005;100:c120-5 pubmed
    ..To determine whether bezafibrates have adverse effects on renal function...
  38. Jonkers I, Mohrschladt M, Westendorp R, van der Laarse A, Smelt A. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. Am J Med. 2002;112:275-80 pubmed
    ..In addition, we investigated whether fibrates reverse this inflammatory state...
  39. Farnier M, Salko T, Isaacsohn J, Troendle A, Dejager S, Gonasun L. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil). Am J Cardiol. 2003;92:794-7 pubmed
    ..Patients received a combination of fluvastatin and a fibrate (bezafibrate, fenofibrate, or gemfibrozil) from 16 to 108 weeks...
  40. Mallordy A, Poirier H, Besnard P, Niot I, Carlier H. Evidence for transcriptional induction of the liver fatty-acid-binding-protein gene by bezafibrate in the small intestine. Eur J Biochem. 1995;227:801-7 pubmed
    The effect of bezafibrate on cytosolic fatty-acid-binding-protein (FABPc) production along the small intestine has been investigated in mice...
  41. Krysiak R, Gdula Dymek A, Okopien B. Monocyte-suppressing effect of bezafibrate but not omega-3 fatty acids in patients with isolated hypertriglyceridaemia. Basic Clin Pharmacol Toxicol. 2011;109:23-9 pubmed publisher
    ..The aim of this study was to compare the effect of bezafibrate and omega-3 fatty acids on monocyte cytokine release and systemic inflammation in this type of dyslipidaemia...
  42. Nakajima T, Tanaka N, Kanbe H, Hara A, Kamijo Y, Zhang X, et al. Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in mice: a novel peroxisome proliferator-activated receptor alpha-independent mechanism. Mol Pharmacol. 2009;75:782-92 pubmed publisher
    The triglyceride-lowering effect of bezafibrate in humans has been attributed to peroxisome proliferator-activated receptor (PPAR) alpha activation based on results from rodent studies...
  43. Manfredi R, Chiodo F. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. J Infect. 2001;42:181-8 pubmed
    To assess the correlation between antiretroviral treatment and dyslipidaemia in HIV-infected patients, and the role of bezafibrate as a lipid-lowering agent.
  44. Pauciullo P, Borgnino C, Paoletti R, Mariani M, Mancini M. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). Atherosclerosis. 2000;150:429-36 pubmed
    ..Treatment Study examined the effects on plasma lipids and safety of a combination of fluvastatin and bezafibrate in patients with coronary artery disease and mixed hyperlipidaemia...
  45. Ackerman Z, Oron Herman M, Rosenthal T, Pappo O, Link G, Sela B, et al. Effects of amlodipine, captopril, and bezafibrate on oxidative milieu in rats with fatty liver. Dig Dis Sci. 2008;53:777-84 pubmed
    ..b>Bezafibrate increased alpha-tocopherol concentration and PON activity, but decreased the activity of GSSG-R...
  46. Kagawa H, Nomura S, Nagahama M, Ozaki Y, Fukuhara S. Effect of bezafibrate on soluble adhesion molecules and platelet activation markers in patients with connective tissue diseases and secondary hyperlipidemia. Clin Appl Thromb Hemost. 2001;7:153-7 pubmed
    ..secondary hyperlipidemia caused by long-term steroid administration (n = 22) before and after treatment with bezafibrate. There were differences in levels of platelet activation markers both before and after treatment (platelet ..
  47. Fujita N, Kaito M, Kai M, Sugimoto R, Tanaka H, Horiike S, et al. Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin. J Viral Hepat. 2006;13:441-8 pubmed
    ..We conducted a prospective study in CHC patients complicated with hyperlipidaemia, to examine whether bezafibrate, which is commonly used for treatment of hyperlipidaemia, reduces serum HCV-RNA titre and improves liver ..
  48. Tenenbaum A, Motro M, Fisman E, Adler Y, Shemesh J, Tanne D, et al. Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J. 2005;26:2032-8 pubmed
    To assess the effect of fibric acid derivative bezafibrate on incidence of type 2 diabetes in obese patients over a median 6.3 years follow-up period.
  49. Zhao Y, Okuyama M, Hashimoto H, Tagawa Y, Jomori T, Yang B. Bezafibrate induces myotoxicity in human rhabdomyosarcoma cells via peroxisome proliferator-activated receptor alpha signaling. Toxicol In Vitro. 2010;24:154-9 pubmed publisher
    ..This study was designed to investigate the effects of bezafibrate as a PPARalpha agonist on human embryo rhabdomyosarcoma (RD) cells and possible mechanisms responsible for ..
  50. Hidaka M, Iwasaki S, Matsui T, Kawakita T, Inoue Y, Sakai T, et al. Efficacy of bezafibrate for chronic GVHD of the liver after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010;45:912-8 pubmed publisher
    ..b>Bezafibrate (BF) is a widely used agent for hyperlipidemia that is also effective in ursodeoxycholic acid (UDCA)-resistant ..
  51. Kita R, Takamatsu S, Kimura T, Kokuryu H, Osaki Y, Tomono N. Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels. J Gastroenterol. 2006;41:686-92 pubmed
    b>Bezafibrate is a commonly used medicine for hyperlipidemia, and recently several reports have suggested the efficacy of bezafibrate for the treatment of primary biliary cirrhosis (PBC)...
  52. Kim J, Tsujino T, Fujioka Y, Saito K, Yokoyama M. Bezafibrate improves hypertension and insulin sensitivity in humans. Hypertens Res. 2003;26:307-13 pubmed
    ..insulin sensitivity in patients with mild essential hypertension and hyperlipidemia, and investigated whether bezafibrate, a lipid-lowering drug, could improve elevated blood pressure and insulin sensitivity in these subjects by ..
  53. Poirier H, Niot I, Monnot M, Braissant O, Meunier Durmort C, Costet P, et al. Differential involvement of peroxisome-proliferator-activated receptors alpha and delta in fibrate and fatty-acid-mediated inductions of the gene encoding liver fatty-acid-binding protein in the liver and the small intestine. Biochem J. 2001;355:481-8 pubmed
    ..We propose that PPARdelta contributes to metabolic adaptation of the small intestine to changes in the lipid content of the diet...